^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    COX2 inhibitor

    Related drugs:
    22h
    Perioperative propranolol and celecoxib (ProCel) in stage III melanoma (ACTRN12624001353583)
    P2, N=40, Withdrawn, Sydney Local Health District | Not yet recruiting --> Withdrawn
    Trial withdrawal • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • B2M (Beta-2-microglobulin) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • MITF (Melanocyte Inducing Transcription Factor)
    |
    celecoxib oral
    3d
    Toxicological Effects of Thymoquinone in Combination With Celecoxib and Irinotecan on DNA Damage, Oxidative Stress, G2/M Arrest, Apoptosis, and Inflammatory Response in SW620 Cells. (PubMed, J Biochem Mol Toxicol)
    In conclusion, this study shows that the combination of TQ with IR, Clx, or both exerts significant effects on SW620 colon cancer cells, such that by enhancing DNA damage, TQ may induce G2/M cell cycle arrest and apoptosis, while reducing inflammatory responses, oxidative stress, and G0/G1 cell cycle arrest. These in vitro findings indicate that TQ may enhance the chemotherapeutic effects of IR and act as a potential adjuvant therapy; however, further in vivo studies are required to verify its suggested effects.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    irinotecan • celecoxib oral
    6d
    A Single-Center, Randomized Controlled Clinical Study of Injectable Hyaluronidase Combined with Celecoxib Capsules for the Treatment of Osteoarthritis (ChiCTR2600117280)
    P=N/A, N=50, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial
    |
    celecoxib oral
    6d
    Iguratimod for Knee Osteoarthritis: A Study on Efficacy and Safety (ChiCTR2500114750)
    P=N/A, N=600, Not yet recruiting, Beijing Jishuitan Hospital, Capital Medical University; Beijing Jishuitan Hospital, Capital Medical University
    New trial
    6d
    A Multicenter, Randomized, Double-Blind, Active Drug/Placebo-Controlled Parallel-Group Clinical Trial on the Efficacy and Safety of Indomethacin Gel Patch in the Treatment of Knee Osteoarthritis (ChiCTR2500112041)
    P=N/A, N=450, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hainan Huiyuantang Pharmaceutical Co., Ltd.
    New trial
    6d
    Clinical study of the ability of celecoxib combined with olanzapine and paroxetine hydrochloride to improve depression,anxiety and analgesic effects in patients after hemorrhoidal surgery (ChiCTR2500112052)
    P=N/A, N=60, Completed, Affiliated Hospital of Jining Medical University; Affiliated Hospital of Jining Medical University
    New trial
    |
    celecoxib oral • olanzapine
    9d
    The combination of rosuvastatin and meloxicam enhances the radiotherapy efficacy of MCF7, T-47D, and MDA-MB-231 breast cancer cell lines. (PubMed, Res Pharm Sci)
    The combination of rosuvastatin and meloxicam at specific concentrations increased the radiation sensitivity of MCF-7, T-47D, and MDA-MB-231 cells. Combined pretreatment with rosuvastatin 10 μM and meloxicam 50 μM notably enhanced genotoxicity while reducing colony formation, catalase activity, and SOD activity compared to radiotherapy alone in MCF-7, T-47D, and MDA-MB-231 cell lines.
    Preclinical • Journal
    |
    CAT (Catalase)
    14d
    Timed Aspirin Chronobiome Study (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, University of Pennsylvania | Trial completion date: May 2028 --> Nov 2028 | Trial primary completion date: May 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    aspirin • celecoxib oral
    14d
    Research Progress of Cyclooxygenase-2 in Colorectal Adenomas. (PubMed, Cancer Biother Radiopharm)
    COX-2 is a critical early-event biomarker and therapeutic target in colorectal adenomas. Targeting the COX-2 pathway represents a viable strategy for prevention, although challenges regarding safety and personalized application remain.
    Review • Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    |
    celecoxib oral
    17d
    A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis (clinicaltrials.gov)
    P1, N=200, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
    New P1 trial
    |
    celecoxib oral
    21d
    Opioid-Sparing Joint Replacement (clinicaltrials.gov)
    P3, N=120, Not yet recruiting, Emory University
    New P3 trial
    24d
    The Effect of Multimodal Pain Regimen on Use of Narcotics After Rotator Cuff Tear Repair (clinicaltrials.gov)
    P4, N=130, Recruiting, Montefiore Medical Center | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    dexamethasone injection